MedTrace Logo

Comparative Evaluate the Efficacy to Acute and Chronic Bronchitis

NCT01979926 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2014-05-30

No results posted yet for this study

Summary

The Purpose of A Multicenter, Randomized, Double-blind, Placebo-controlled to Evaluate the Efficacy, Safety and Pharmacokinetics of N02RS1 600mg and 1,200mg per day in Patients With acute and acute exacerbation of chronic bronchitis for 7 days.

Conditions

  • Acute Exacerbation of Chronic Bronchitis

Interventions

DRUG

Combination of Broussonetia spp and Lonicera spp

600 mg/ day or 1200 mg/ day for 7 days

Sponsors & Collaborators

  • PharmaKing

    lead INDUSTRY

Principal Investigators

  • Wayne B An, Bs · Korea Pharmaceutical Manufacturers Association

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2013-11-30
Completion
2014-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01979926 on ClinicalTrials.gov